KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Total Liabilities (2016 - 2025)

Inovio Pharmaceuticals' Total Liabilities history spans 16 years, with the latest figure at $7.7 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 76.97% year-over-year to $7.7 million; the TTM value through Sep 2025 reached $7.7 million, down 76.97%, while the annual FY2024 figure was $44.7 million, 16.62% down from the prior year.
  • Total Liabilities for Q3 2025 was $7.7 million at Inovio Pharmaceuticals, down from $39.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $161.7 million in Q2 2022 and bottomed at -$94.4 million in Q1 2024.
  • The 5-year median for Total Liabilities is $63.7 million (2023), against an average of $62.2 million.
  • The largest annual shift saw Total Liabilities crashed 240.19% in 2024 before it surged 138.14% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $96.3 million in 2021, then skyrocketed by 31.06% to $126.2 million in 2022, then tumbled by 57.52% to $53.6 million in 2023, then fell by 16.62% to $44.7 million in 2024, then tumbled by 82.73% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Total Liabilities are $7.7 million (Q3 2025), $39.7 million (Q2 2025), and $36.0 million (Q1 2025).